Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 11/20 | 0.50 |
| ▸ | GRM1 | Q13255 | 11/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17886606 | 0.85 | PDK4 (0.38) | PDK4GRM5GRM1NAMPTUSP2 | |
| SCHEMBL26064534 | 0.85 | ESR2 (0.44) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL8218881 | 0.83 | PDK4 (0.51) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL12320441 | 0.83 | PDK4 (0.51) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL12069963 | 0.82 | PDK4 (0.50) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL13177723 | 0.82 | ADORA1 (0.51) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL17886544 | 0.82 | ALDH1A1 (0.42) | SMN1; SMN2 | |
| SCHEMBL16936975 | 0.82 | PDK4 (0.50) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL14301396 | 0.82 | PDK4 (0.50) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL14028045 | 0.82 | PDK4 (0.50) | PDK4GRM5GRM1NAMPTESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-11-09 | — | — | US | disclosed |
| US-11498926-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2022-11-15 | — | — | US | disclosed |
| US-20210323916-A1 | NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2021-10-21 | — | — | US | disclosed |
| US-20210188872-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORTION | 2021-06-24 | — | — | US | disclosed |
| US-10919912-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2021-02-16 | — | — | US | disclosed |
| US-20200392081-A1 | NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2020-12-17 | — | — | US | disclosed |
| US-20200131195-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2020-04-30 | — | — | US | disclosed |
| US-20190099747-A1 | NANO-TO-NANO FE/PPM Pd CATALYSIS OF CROSS-COUPLING REACTIONS IN WATER | UNIV CALIFORNIA (US) | 2019-04-04 | — | — | US | disclosed |
| US-10189016-B2 | Nano-to-nano Fe/ppm Pd catalysis of cross-coupling reactions in water | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-01-29 | — | — | US | disclosed |
| EP-2629771-B1 | USE OF PI3K INHIBITORS FOR THE TREATMENT OF OBESITY, STEATOSIS AND AGEING | FUNDACION CENTRO NAC DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) | 2018-08-08 | — | — | EP | disclosed |
| US-20160289230-A1 | NOVEL AZAINDOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE (HDAC) INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-10-06 | — | — | US | disclosed |
| US-9227985-B2 | Tricyclic heterocycles as bet protein inhibitors | INCYTE CORPORATION (US) | 2016-01-05 | — | — | US | disclosed |
| US-20140275030-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-8815902-B2 | Tetrahydroquinoline amide M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8778935-B2 | Imidazopyrazines for use as kinase inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2014-07-15 | — | — | US | disclosed |
| US-20140154232-A1 | Use of Pl3K Inhibitors for the Treatment of Obesity, Steatosis and Ageing | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2014-06-05 | — | — | US | disclosed |
| US-20130090352-A1 | TETRAHYDROQUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2013-04-11 | — | — | US | disclosed |
| US-20120083492-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2012-04-05 | — | — | US | disclosed |
| US-20120083492-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2012-04-05 | — | — | US | disclosed |
| US-20110166088-A1 | BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | ATG7, GOT1, LIPC | PDK4 558/4885GRM5 4287/4885GRM1 3221/4885 |
| US-20140154232-A1 | Use of Pl3K Inhibitors for the Treatment of Obesity, Steatosis and Ageing | PLIN1, PCK2, PLIN3 | PDK4 21/4885GRM5 2820/4885GRM1 2176/4885 |
| US-20110166088-A1 | BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS | TOP2B, TOP1, POLI | PDK4 37/4885GRM5 3253/4885GRM1 2966/4885 |
| US-20190099747-A1 | NANO-TO-NANO FE/PPM Pd CATALYSIS OF CROSS-COUPLING REACTIONS IN WATER | SOD1, MPO, TFRC | PDK4 478/4885GRM5 3899/4885GRM1 2064/4885 |
| US-20140275030-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | PDK4 2742/4885GRM5 3784/4885GRM1 3673/4885 |
| US-20120083492-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | MTOR, PIK3CA, PI4KA | PDK4 170/4885GRM5 2124/4885GRM1 1701/4885 |
| US-20200131195-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | PDK4 3009/4885GRM5 3789/4885GRM1 3588/4885 |
| US-20210188872-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | PDK4 3009/4885GRM5 3789/4885GRM1 3588/4885 |
| US-20130090352-A1 | TETRAHYDROQUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, OPRM1 | PDK4 3885/4885GRM5 45/4885GRM1 22/4885 |
| US-20210323916-A1 | NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | CYP19A1, ESR1, ESR2 | PDK4 545/4885GRM5 750/4885GRM1 989/4885 |
| US-20200392081-A1 | NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | CYP19A1, ESR1, ESR2 | PDK4 545/4885GRM5 750/4885GRM1 989/4885 |
| US-10189016-B2 | Nano-to-nano Fe/ppm Pd catalysis of cross-coupling reactions in water | SOD1, MPO, TFRC | PDK4 478/4885GRM5 3899/4885GRM1 2064/4885 |
| US-20160289230-A1 | NOVEL AZAINDOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE (HDAC) INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | HDAC5, HDAC1, HDAC2 | PDK4 1230/4885GRM5 825/4885GRM1 2621/4885 |
| US-11498926-B2 | Tricyclic heterocycles as BET protein inhibitors | BRD1, BRD3, BRD2 | PDK4 3009/4885GRM5 3789/4885GRM1 3588/4885 |
| US-10919912-B2 | Tricyclic heterocycles as BET protein inhibitors | BRD1, BRD3, BRD2 | PDK4 3009/4885GRM5 3789/4885GRM1 3588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.